Clinical trial
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety, Anti-tumor Activity, Pharmacokinetic/Pharmacodynamic Characteristics of FXB0871 as Monotherapy in Participants With Selected Locally Advanced or Metastatic Solid Tumors
NCT07558200 is registered in ClinicalTrials.gov with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety, Anti-tumor Activity, Pharmacokinetic/Pharmacodynamic Characteristics of FXB0871 as Monotherapy in Participants With Selected Locally Advanced or Metastatic Solid Tumors
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- May 15, 2026
- Completion date
- November 18, 2030
- Enrollment
- 138 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma, non-small cell lung cancer, solid tumors